In the goal of increasing market opportunities for its biotech innovations, Rainbow Coral is now looking for new overseas targets that could benefit from adding licenses for the drug delivery protocols that its joint venture partner, TheraKine, has developed.
According to some experts, the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015. TheraKine is a leader in this space, having developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery. These technologies promise to lower drug concentrations and significantly reduced risk of drug toxicity.
Focused on building market share in this fast-growing sector, RBCC is targeting overseas healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients.
“Licensing is the key to making this a successful partnership with TheraKine,” said RBCC CEO Patrick Brown. “Together, we can spread this revolutionary technology around the globe to the doctors and patients who need it most.”
For more information on Rainbow BioSciences’ personalized medicine initiatives, please visit www.rainbowbiosciences.com/investors.html
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment